Iodine Status in Pregnancy and Associated Health Outcomes (Hiba)

October 5, 2021 updated by: Darren Greenwood, University of Leeds

Assessing Iodine Status and Associated Health Outcomes in British Women During Pregnancy

Iodine is a key micronutrient in the diet, essential for healthy growth, and is particularly important during pregnancy and breastfeeding when demands are increased to support the developing baby. Many people are thought to lack all the iodine they need, and this is a greater issue during and shortly after pregnancy when the body's iodine requirements are greatest. Iodine deficiency complications are potentially serious for both mother and child. Iodine deficiency can lead to thyroid enlargement, lower production of important hormones produced by the thyroid, pregnancy complications in the mother, and impaired growth and developmental problems in babies and children. This research will focus on providing an up-to-date estimate of how many pregnant women do not have enough iodine, and what different levels of iodine might mean in terms of health risks during pregnancy and for childhood development. The investigators will investigate how iodine levels vary over the course of pregnancy and lactation, how this is affected by diet, associated changes in thyroid size and function, and what levels of iodine are linked with greater risk of subsequent health problems. The research will take advantage of existing urine samples collected from mothers during pregnancy in the Born in Bradford birth cohort study, where the investigators also know of any adverse pregnancy outcomes, as well as any developmental problems for the baby and in early childhood.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Background: Pregnant women may be particularly vulnerable to iodine deficiency as requirements increase to support fetal development. There is limited information concerning how maternal iodine status changes during pregnancy. Severe iodine deficiency is associated with deleterious health outcomes during pregnancy including gestational diabetes, preeclampsia, stillbirth, and increased mortality. For the fetus, severe iodine deficiency results in reduced birthweight, increased mortality and neurodevelopmental issues. Several studies suggest 40% of pregnant mothers in the United Kingdom (UK) may not meet the World Health Organization (WHO) definition of iodine sufficiency. Although the effects of severe iodine deficiency are known, the impact of mild-to-moderate deficiencies on maternal health and associated fetal and childhood development are not well understood.

Aims:

  1. To provide up-to-date information on iodine status in pregnant women in the UK, including changes during pregnancy and lactation, and the role of diet.
  2. To quantify any associations between iodine status during pregnancy, pregnancy outcomes, and cognitive and motor development of the child.
  3. To compare the iodine status of mothers in the Born in Bradford cohort to a more nationally representative sample.

Research plan and methods: The investigators will utilize the Born in Bradford (BiB) birth cohort which recruited over 12000 pregnant women between 2007- 2009, and has deposited in a biobank 6971 spot urine samples collected at 26-28 weeks gestation.

Data are available on health outcomes during pregnancy including gestational diabetes, preeclampsia, blood pressure, length of gestation, mortality, mental health. Child outcome measures at birth include weight, length, head circumference, small-for-gestational-age. Childhood developmental measures include height, weight, growth trajectories, motor skills, literacy, numeracy and mental health (Strengths and Difficulties Questionnaire, SDQ). Linkage with educational outcomes has been achieved, including Early Years Foundation Stage (EYFS) outcomes and Standard Assessment Tests (SATS) at both Key Stage 1 (KS1) and Key Stage 2 (KS2).

The investigators will measure all maternal urine samples in BiB to allow sufficient power to detect potential modest-sized associations. This will be conducted using Inductively Coupled Plasma Mass Spectrometry (ICPMS). All maternal baseline characteristics and associated outcome data are available for extraction from the primary BiB database.

The investigators will apply multiple logistic regression and multiple linear regression to ascertain potential associations between maternal iodine status and health and developmental outcomes. Cubic splines will be used to model any nonlinear dose-response associations, making no assumptions regarding any predefined thresholds.

The investigators will also conduct a longitudinal substudy to ascertain how iodine status varies between trimesters (The Hiba study). 200 pregnant women will be recruited at 12 week dating scans and the following collected: baseline characteristics, urine samples for iodide analysis, blood for thyroid stimulating hormone (TSH), free thyroxine (fT4) and triiodothyronine (fT3), thyroglobulin, Glomerular Filtration Rate (GFR) based on serum creatinine, visual inspection of the thyroid using standard methods, dietary intake using a validated online 24h recall tool (myfood24). Data collection will be repeated at 26 and 36 weeks' gestation, and 6, 18 and 30 weeks postpartum. The proposed substudy will clarify how iodine status alters in pregnancy and lactation, and any associated thyroid hormone changes. The investigators will identify key sources of iodine in the diet and ascertain dietary patterns associated with different iodine status. To compare results to a more nationally representative sample, spot urines will be analysed from approximately 650 women in the SCOPE birth-cohort (London, Leeds and Manchester).

Study Type

Observational

Enrollment (Actual)

246

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 40 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

The Born in Bradford cohort profile is published here: [doi:10.1093/ije/dys112] All women booked for delivery at the Bradford Royal Infirmary at 26-28 weeks gestation. All of the recruited women who provided urine samples are included in our Born in Bradford analysis.

The Hiba longitudinal study replicates this process, but at the 12 week dating scan.

Description

Inclusion criteria:

  • Female (Both Born in Bradford and Hiba longitudinal cohorts)
  • Able to provide informed consent (Both Born in Bradford and Hiba longitudinal cohorts)
  • Confirmed pregnant at 26-28 week Oral Glucose Tolerance Test (OGTT) (Born in Bradford cohort)
  • Confirmed 9-15 weeks pregnant at 12 week dating scan (Hiba longitudinal cohort)
  • Aged 18-40 years (Hiba longitudinal cohort)
  • No medical or known first degree family history of a thyroid condition (Hiba longitudinal cohort).

Exclusion criteria:

  • Inability to provide informed consent (Both Born in Bradford and Hiba longitudinal cohorts)
  • Current or former medical history of thyroid disease (Hiba longitudinal cohort)
  • Use of thyroid related medications (Hiba longitudinal cohort)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Born in Bradford: Early Years Foundation Stage (EYFS) profiles
Time Frame: Ages 3 to 5
The EYFS average points total over 17 domains (score range 17 to 41) and summarised using achievement of Good Level of Development (GLD) (binary).
Ages 3 to 5

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Born in Bradford: Key Stage 1 (KS1) educational outcomes
Time Frame: Ages 5 to 8
Year 1 phonics screening test (score range 0 to 40) and KS1 SATS scores in Reading, Writing, Mathematics and Science (working securely at level 2b or beyond pre-2016 or working at the expected standard or beyond for 2016 onwards, binary) will be presented.
Ages 5 to 8
Born in Bradford: Letter identification
Time Frame: Ages 3 to 5
Letter identification (standardised)
Ages 3 to 5
Born in Bradford: Receptive vocabulary
Time Frame: Ages 3 to 5
Receptive vocabulary using the British Picture Vocabulary Scale (BPVS)(standardised)
Ages 3 to 5
Born in Bradford: Social functioning
Time Frame: Ages 3 to 5
Social functioning using the Strengths and Difficulties Questionnaire (SDQ) total difficulty score and split by domains (e.g. internalising and externalising)
Ages 3 to 5
Born in Bradford: Fine motor skills
Time Frame: Ages 3 to 5
Fine motor skills using the Clinical Kinematic Assessment Tool (CKAT) overall battery score, along with Tracking, Aiming and Tracing CKAT sub-scores.
Ages 3 to 5
Born in Bradford: Birth weight centile
Time Frame: At birth
The main birth outcome of interest is birth weight centile, calculated using the version 8.0.1 of the Bulk centile calculator provided by the Gestation Network based at the Perinatal Institute for Maternal and Child Health
At birth
Born in Bradford: Apgar score
Time Frame: At 1 minute and 5 minutes after birth.
Apgar score (ordinal).
At 1 minute and 5 minutes after birth.
Born in Bradford: Diagnosis of autism
Time Frame: Up to age 11.
Confirmed diagnosis of autism based on Read codes in linked General Practitioner records.
Up to age 11.
Born in Bradford: Diagnosis of attention deficit hyperactivity disorder (ADHD)
Time Frame: Up to age 11.
Confirmed diagnosis of attention deficit hyperactivity disorder (ADHD) based on Read codes in linked General Practitioner records.
Up to age 11.
Hiba longitudinal study: Urinary iodine status
Time Frame: 12, 26 and 36 weeks' gestation during pregnancy, and 6, 18 and 30 weeks' postpartum.
The main outcome of interest is urinary iodine status (primarily in the form of iodine to creatinine ratio to take account of spot urine volumes) changes during pregnancy and lactation (continuous)
12, 26 and 36 weeks' gestation during pregnancy, and 6, 18 and 30 weeks' postpartum.
Hiba longitudinal cohort: thyroid stimulating hormone (TSH)
Time Frame: 12, 26 and 36 weeks' gestation during pregnancy, and 6, 18 and 30 weeks' postpartum.
Changes in thyroid stimulating hormone (TSH) during gestation and lactation.
12, 26 and 36 weeks' gestation during pregnancy, and 6, 18 and 30 weeks' postpartum.
Hiba longitudinal cohort: triiodothyronine (fT3)
Time Frame: 12, 26 and 36 weeks' gestation during pregnancy, and 6, 18 and 30 weeks' postpartum.
Changes in triiodothyronine (fT3) during gestation and lactation.
12, 26 and 36 weeks' gestation during pregnancy, and 6, 18 and 30 weeks' postpartum.
Hiba longitudinal cohort: free thyroxine (fT4)
Time Frame: 12, 26 and 36 weeks' gestation during pregnancy, and 6, 18 and 30 weeks' postpartum.
Changes in free thyroxine (fT4) during gestation and lactation.
12, 26 and 36 weeks' gestation during pregnancy, and 6, 18 and 30 weeks' postpartum.
Hiba longitudinal cohort: thyroglobulin
Time Frame: 12, 26 and 36 weeks' gestation during pregnancy, and 6, 18 and 30 weeks' postpartum.
Changes in thyroglobulin during gestation and lactation.
12, 26 and 36 weeks' gestation during pregnancy, and 6, 18 and 30 weeks' postpartum.
Hiba longitudinal cohort: thyroid size
Time Frame: 12, 26 and 36 weeks' gestation during pregnancy, and 6, 18 and 30 weeks' postpartum.
Changes in thyroid size, measured by palpation, using a standard protocol, during gestation and lactation.
12, 26 and 36 weeks' gestation during pregnancy, and 6, 18 and 30 weeks' postpartum.
Hiba longitudinal cohort: maternal dietary iodine intake (micrograms)
Time Frame: 12, 26 and 36 weeks' gestation during pregnancy, and 6, 18 and 30 weeks' postpartum.
Identification of highest ranking food items in terms of contribution to iodine in the maternal diet as measured using the myfood24 tool
12, 26 and 36 weeks' gestation during pregnancy, and 6, 18 and 30 weeks' postpartum.

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Born in Bradford: length of gestation
Time Frame: At birth
length of gestation (weeks), presenting pre-term delivery (<37 weeks)
At birth
Born in Bradford: congenital anomalies
Time Frame: At birth
Diagnosis of congenital anomalies from linked congenital anomalies records (binary)
At birth
Born in Bradford: childhood growth trajectories
Time Frame: From 26 weeks gestation, through to age 11
Childhood growth trajectories (weight in kg)
From 26 weeks gestation, through to age 11
Born in Bradford: Key Stage 2 (KS2) educational outcomes
Time Frame: Ages 8 to 11
Key Stage 2 (KS2) SATS scores in English grammar, punctuation and spelling, English reading, and Mathematics.
Ages 8 to 11
Born in Bradford: maternal mental health
Time Frame: From 26 weeks gestation, through to age 11
Patient Health Questionnaire 9 (PHQ-9) depression test questionnaire
From 26 weeks gestation, through to age 11

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Darren C Greenwood, PhD, University of Leeds
  • Principal Investigator: Laura J Hardie, PhD, University of Leeds

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2016

Primary Completion (Actual)

March 31, 2019

Study Completion (Actual)

March 31, 2019

Study Registration Dates

First Submitted

May 11, 2018

First Submitted That Met QC Criteria

June 8, 2018

First Posted (Actual)

June 11, 2018

Study Record Updates

Last Update Posted (Actual)

October 14, 2021

Last Update Submitted That Met QC Criteria

October 5, 2021

Last Verified

October 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PR-R10-0514-11004

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Born in Bradford welcomes collaboration with other researchers. The BiB website has details of how to submit expressions of interest and has short proformas for these. All suggestions will be reviewed by the BiB Executive Group on a monthly basis, and we aim to get back to potential collaborators within 8 weeks.

IPD Sharing Time Frame

Ongoing.

IPD Sharing Access Criteria

Submit expressions of interest on a short proforma. All suggestions will be reviewed by the BiB Executive Group.

Study Data/Documents

  1. Individual Participant Data Set
    Information comments: Submit expressions of interest on a short proforma. All suggestions will be reviewed by the BiB Executive Group.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Birth Weight

Clinical Trials on Maternal iodine status

3
Subscribe